Colleen27
DIS Legend
- Joined
- Mar 31, 2007
- Messages
- 24,190
Substitute the word “countries” with “states” or “counties” and it’ll describe the situation in the US.
But we have some level of cooperative coordination. Some might not like the specifics of it, particularly IRT equity efforts or which professions are singled out for earlier access, but we don't have states fighting over allocation or bidding against one another for vaccine contracts. It seems like the EU is suffering from too many cooks in the kitchen, with EU regulators saying one thing and country health authorities saying another and with the EU handling some of the contracts/distribution but countries also trying to run their own contracts and programs as well.
We've also had better luck, for lack of a better word, with the vaccines that we've approved so far - A-Z/Oxford seemed like the leading European jab for a while there and seemed to be the one everyone wanted, but they've also been the one that has had the most problems that caused delays and suspensions of the vaccination program. Maybe that's the difference in EU vs. US regulatory standards at play, but it seems like A-Z has had more associated adverse events and temporary pauses in administration than Pfizer or Moderna.